Several PARP inhibitors have received FDA approval for cancer treatment, including Talazoparib, Rucaparib, Niraparib, and Olaparib (Min and Im, 2020; Pascal, 2018; Slade, 2020). The gene discussed is PARP1; the disease is cancer.